Sanford Guide subscription cost: every published price for the antimicrobial guide, web edition and app

No. Both apps, the antimicrobial guide and the pediatric one, download free from the US App Store and Google Play, and that is what makes people ask. The download is free and the content behind it is not. Opening the app without a subscription gets you a login screen, so the free download is a delivery mechanism rather than a free tier.

That distinction matters more than it sounds, because two of the references clinicians reach for alongside this one really are free at the point of use. Medscape is free and ad-funded. OpenEvidence is free to NPI-verified US clinicians and also ad-funded. Sanford Guide has no equivalent. There is no permanently free level, no limited question count, no free tier with ads. You subscribe or you do not have it.

There is a free trial, but you request it rather than start it. The vendor runs a trial request form where you submit your details and say which product you want to evaluate, and institutional trials go through the same route. Plan for a wait rather than an instant signup, and use the trial to answer one question: do you reach for the phone, the browser, or both. That answer picks your tier.

Line up what every major point-of-care reference will tell you about its own price and a pattern falls out that has nothing to do with software quality. Sanford Guide publishes eleven individual prices down to a $4.99 module. Johns Hopkins publishes $39.95 and $89.95. Epocrates publishes $179.99. Lexidrug publishes $29.99 a month. Then you reach UpToDate, DynaMed, DynaMedex and Micromedex, and the published price at every tier is nothing at all.

The dividing line is who signs the check. Products bought by one clinician with a personal credit card show a price, because a person who cannot see a price does not buy. Products sold into a procurement department publish nothing, because the number is negotiated per institution and publishing it would set a ceiling on every negotiation. Transparency here tracks the sales motion, not the product.

Which is why the last row of the rate card above is worth as much attention as the first ten. Sanford Guide sells individual, workstation, facility and enterprise-wide licenses with single sign-on and off-site access through EZProxy, and none of those carry a public number. The same vendor that will tell you a vaccine module costs $4.99 will not tell you what a hospital pays. We measure the same asymmetry brand by brand in the UpToDate subscription cost guide and the OpenEvidence cost breakdown.

This is the point most pricing pages skip, and it changes the real number you will spend. Sanford Guide covers infectious disease. It does that in more depth than any general reference, organized by syndrome and by pathogen, with spectra of activity tables and anti-infective dosing. It is not a general drug compendium and has never claimed to be.

So if your prescribing questions are mostly antimicrobial, $79.99 a year is an easy call. If they are not, you are pricing a narrow tool against a broad one, and those are different purchases. A hospitalist who needs interaction screening across a ten-drug list, contraindication checks against comorbidities, and renal dose adjustment across every class is describing a compendium, and the antimicrobial guide will answer perhaps a fifth of it.

The honest arithmetic for most buyers is additive rather than either-or: a broad reference for daily prescribing plus Sanford Guide for the infectious disease depth. At $79.99 that second subscription is cheap, and stewardship pharmacists and ID physicians rarely need convincing. It is worth naming out loud, though, because the comparison that gets made in a budget meeting is usually Sanford against Epocrates on price alone, and on that framing the cheaper one looks like the winner when it is answering a smaller question. Our drug reference app comparison scores the broad tools against each other on that basis.

These two are the real head to head, because they are the two subscription products aimed squarely at the same job, and Johns Hopkins is genuinely cheaper. The ABX Guide is $39.95 a year against $79.99 for Sanford Guide All Access. That is half the price for the same category of content, and any honest comparison has to start by saying so.

The bundle changes the shape of it. Unbound Medicine sells four Johns Hopkins guides together, ID plus HIV, diabetes and psychiatry, for $89.95 a year. Against a single Sanford Guide subscription at $79.99 that is $9.96 more for three additional specialty references, which is a strong offer if any of those three are relevant to you and irrelevant if they are not.

Price is where the comparison ends cleanly and preference begins. Sanford Guide has been the format clinicians learned on for over fifty years, and people who work from it tend to be fast in it in a way that does not transfer. That familiarity is worth $40 a year to a lot of subscribers and nothing at all to someone starting fresh. If you have never used either, the cheaper one deserves the trial first, and the vendor will not mind us saying so.

On price, yes, and quickly. The Library Edition costs $57.99 once. The Web Edition costs $59.99 every year. By month fourteen the book is ahead, and by year three it is ahead by more than a hundred dollars. The Pocket Edition at $37.99 makes the arithmetic starker still.

The catch is not a small one. Antimicrobial guidance moves. Resistance patterns shift, society recommendations get revised, and labeled dosing changes. A printed edition freezes on its publication date and the digital subscription does not, which is the entire reason the subscription exists. Buying print to save money means accepting a reference that is correct on the day it ships and progressively less so afterward.

The sensible way to hold both facts at once is to buy print for the format rather than for the saving. A spiral-bound book that lies flat on a workroom desk is genuinely nicer to use than a phone, and plenty of clinicians keep one alongside a subscription for exactly that reason. What does not work is treating the book as a cheaper subscription, because it is not a subscription at all. It is a snapshot, and its value decays on a schedule you do not control.